Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Els
E
Lierman
Dominik
D
Selleslag
Sanne
S
Smits
Johan
J
Billiet
Peter
P
Vandenberghe
D000368:Aged; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000473:pathology*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D020732:Cytogenetic Analysis; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy / Q000235:genetics*; D053614:Janus Kinase 2 / Q000378:metabolism*; D008297:Male; D009570:Nitriles; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines; D012074:Remission Induction; D014178:Translocation, Genetic / Q000187:drug effects*
D009570:Nitriles; D015514:Oncogene Proteins, Fusion; C575876:PCM1-JAK2 fusion protein, human; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053614:Janus Kinase 2